The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma*

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Biological Chemistry

• Publication date

  2015-10-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1074/jbc.M115.664953PMID 26483548PMCID PMC4705994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.

  2015cited by this paper
• Nrf 2 , a regulator of the proteasome , controls self-renewal and pluripotency in human embryonic stem cells

  2014cited by this paper
• Nrf2, a Regulator of the Proteasome, Controls Self‐Renewal and Pluripotency in Human Embryonic Stem Cells

  2014cited by this paper
• Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

  2014cited by this paper
• Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer.

  2014cited by this paper
• RARA fusion genes in acute promyelocytic leukemia: a review

  2014cited by this paper
• Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

  2014cited by this paper
• Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

  2013cited by this paper
• Why proteasome inhibitors cannot ERADicate multiple myeloma.

  2013cited by this paper
• Multiple myeloma, version 1.2013.

  2013cited by this paper
• Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

  2013cited by this paper
• Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.

  2013cited by this paper
• Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

  2013cited by this paper
• Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma

  2013cited by this paper
• The emerging role of the Nrf2–Keap1 signaling pathway in cancer

  2013cited by this paper
• Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

  2013cited by this paper
• Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population‐based analysis

  2013cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• Nrf2-dependent Induction of Proteasome and Pa28αβ Regulator Are Required for Adaptation to Oxidative Stress*

  2012cited by this paper
• New Proteasome Inhibitors in Myeloma

  2012cited by this paper
• Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

  2012cited by this paper
• Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

  2012cited by this paper
• Latest advances and current challenges in the treatment of multiple myeloma

  2012cited by this paper
• Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha

  2012cited by this paper
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

  2012cited by this paper
• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

  2012cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

  2012influential reference
• Small Molecule Modulators of Keap1‐Nrf2‐ARE Pathway as Potential Preventive and Therapeutic Agents

  2012cited by this paper
• Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland

  2011cited by this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cited by this paper
• Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

  2010cited by this paper
• Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.

  2010cited by this paper
• A Novel Testis-specific GTPase Serves as a Link to Proteasome Biogenesis: Functional Characterization of RhoS/RSA-14-44 in Spermatogenesis

  2010cited by this paper
• The effects of proteasome inhibitor bortezomib on a P‐gp positive leukemia cell line K562/A02

  2010cited by this paper
• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

  2010cited by this paper
• Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells.

  2010cited by this paper
• Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein

  2009cited by this paper
• The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

  2009cited by this paper
• Catalytic mechanism and assembly of the proteasome.

  2009influential reference
• Molecular mechanisms of proteasome assembly

  2009cited by this paper
• Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

  2009cited by this paper
• Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

  2008cited by this paper
• Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells

  2008cited by this paper
• Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

  2008cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

  2008cited by this paper
• Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.

  2008cited by this paper
• Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha

  2007cited by this paper
• The proteasome maturation protein POMP facilitates major steps of 20S proteasome formation at the endoplasmic reticulum

  2007cited by this paper
• Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

  2007cited by this paper
• Overexpression of hUMP1/POMP proteasome accessory protein enhances proteasome-mediated antioxidant defence.

  2007cited by this paper
• No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.

  2006cited by this paper
• Progressively impaired proteasomal capacity during terminal plasma cell differentiation

  2006cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase To Regulate Proteasomal Degradation of Nrf2

  2004cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Antioxidants Enhance Mammalian Proteasome Expression through the Keap1-Nrf2 Signaling Pathway

  2003cited by this paper
• Inhibition of Proteasome Activity Induces Concerted Expression of Proteasome Genes and de Novo Formation of Mammalian Proteasomes*

  2003cited by this paper
• Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(beta 5i) incorporation into 20 S proteasomes.

  2000cited by this paper

• Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival

  2026cites this paper
• The clinical-grade CBP/ p300 inhibitor CCS1477 represses the global NRF2-dependent cytoprotective transcription program and re-sensitizes cancer cells to chemotherapeutic drugs.

  2025cites this paper
• Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma

  2025cites this paper
• The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells

  2025cites this paper
• NRF2 inhibitors: Recent progress, future design and therapeutic potential.

  2024cites this paper
• Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells

  2024cites this paper
• Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors

  2024cites this paper
• NRF-Mediated Autophagy and UPR: Exploring New Avenues to Overcome Cancer Chemo-Resistance.

  2024cites this paper
• TAZ upregulates MIR‐224 to inhibit oxidative stress response in multiple myeloma

  2023cites this paper
• Targeting the NF-E2-related factor 2 pathway for overcoming leukemia.

  2023cites this paper
• Major genomic mutations driving hepatocellular carcinoma

  2023cites this paper
• Nrf2: A promising therapeutic target in bone-related diseases.

  2023cites this paper
• Influence of endoplasmic reticulum stress and unfolded protein response in the onset and progression of hepatocellular carcinoma

  2022cites this paper
• Novel NRF2‐activated cancer treatments utilizing synthetic lethality

  2022cites this paper
• Nrf2 and oxidative stress in liver ischemia/reperfusion injury

  2021cites this paper
• Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

  2021cites this paper
• Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma

  2021cites this paper
• Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease

  2021cites this paper
• Prognostic Value of Resistance Proteins in Plasma Cells From Multiple Myeloma Patients Treated With Bortezomib

  2021influential citation
• Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation

  2021cites this paper
• Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance

  2021cites this paper
• Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

  2021cites this paper
• Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells

  2021cites this paper
• NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein

  2020cites this paper
• The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

  2020cites this paper
• The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib

  2020cites this paper
• Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy.

  2020cites this paper
• The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.

  2020cites this paper
• Combinatorial ixazomib and belinostat therapy induces NFE2L2‐dependent apoptosis in Hodgkin and T‐cell lymphoma

  2020cites this paper
• Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

  2020cites this paper
• The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer

  2020cites this paper
• Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.

  2020cites this paper
• NRF2, a Transcription Factor for Stress Response and Beyond

  2020cites this paper
• The Proteasome System in Health and Disease.

  2020cites this paper
• Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies

  2019cites this paper
• The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies

  2019cites this paper
• LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p

  2019cites this paper
• Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP

  2019cites this paper
• Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

  2019cites this paper
• Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

  2019cites this paper
• Mitochondrial metabolism promotes adaptation to proteotoxic stress

  2019cites this paper
• Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma

  2019cites this paper
• New addiction to the NRF2‐related factor NRF3 in cancer cells: Ubiquitin‐independent proteolysis through the 20S proteasome

  2019cites this paper
• Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

  2019cites this paper
• Resistance to proteasome inhibitors and other targeted therapies in myeloma

  2018cites this paper
• Resistance Mechanisms to Novel Therapies in Myeloma

  2018cites this paper
• Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity

  2018cites this paper
• Inhibition of mitochondrial ferredoxin 1 (FDX1) prevents adaptation to proteotoxic stress

  2018cites this paper
• NRF2 and the Hallmarks of Cancer.

  2018cites this paper
• Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent

  2018cites this paper
• Protein Targeting Chimeric Molecules Specific for Bromodomain and Extra-terminal Motif Family Proteins are Active Against Pre-Clinical Models of Multiple Myeloma

  2018cites this paper
• Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update

  2018cites this paper
• NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma

  2018cites this paper
• Drug resistance in multiple myeloma.

  2018cites this paper
• Regulation of proteasome assembly and activity in health and disease

  2018cites this paper
• Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.

  2018cites this paper
• Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma

  2018cites this paper
• The start of a new wave: Developments in proteasome inhibition in multiple myeloma

  2018cites this paper
• Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance

  2018cites this paper
• Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma

  2017cites this paper
• Antioxidant Systems, Thioredoxin and DJ-1: Novel Therapeutic Targets in Multiple Myeloma

  2017cites this paper
• The proteasome maturation protein POMP increases proteasome assembly and activity in psoriatic lesional skin.

  2017cites this paper
• Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfilzomib-resistant multiple myeloma cells and high-risk multiple myeloma patients

  2017cites this paper
• Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma

  2017cites this paper
• Live kinase B1 maintains CD34+CD38− AML cell proliferation and self-renewal

  2017cites this paper
• Proteasome inhibitors in cancer therapy

  2017cites this paper
• Shadows of NRF2 in cancer: Resistance to chemotherapy

  2016cites this paper
• Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

  2016cites this paper
• Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers

  2016cites this paper
• Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming

  2016cites this paper
• Investigating Mechanisms Determining Cancer Cell Sensitivity to Carfilzomib and Novel Strategies to Overcome Resistance

  2016cites this paper
• Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

  2016cites this paper
• Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma

  2015cites this paper